Job title: Senior Scientist II
Andrew received his PhD in Molecular, Cellular, and Integrative Physiology from UCLA. His dissertation research was on the cell signaling pathways that regulate contraction and migration of hepatic stellate cells. As a postdoc at UCSF, he studied the role of integrin αvβ8-mediated TGFβ activation in autoimmune disease. For the past six years at BioMarin Pharmaceutical, Inc., Andrew has managed the development and validation of analytical methods for detection of drug, antibodies to protein therapeutics, and biomarkers in nonclinical and human subjects. Recently, he has investigated key questions surrounding gene therapy immunogenicity, and led the development pharmacokinetic, pharmacodynamic and immunogenicity assays for AAV5-based gene therapies.